RNA
Family of large biological molecules
Follow RNA on Notably News to receive short updates to your email — rarely!
We include updates on Nucleotide base, Regulation of gene expression, Ribozyme, Post-transcriptional modification, G-quadruplex, Untranslated region, Nucleic acid sequence, Cis-regulatory element, Ribonucleotide, Transcriptome, Nucleic acid structure, Gene silencing, Five prime untranslated region, Formose reaction, Nucleic acid secondary structure, Three prime untranslated region ... and more.
| 2022 |
RNA interference
FDA and EMA approve vutrisiran for treating adults with hereditary transthyretin mediated amyloidosis with polyneuropathy stage 1 or 2.
|
| November 2022 |
Rfam
Current version 14.9 released, annotating 4,108 RNA families.
|
| 2020 |
RNA interference
FDA approved lumasiran for the treatment of PH1 (Primary Hyperoxaluria Type 1).
|
| 2020 |
RNA interference
FDA approved lumasiran for the treatment of PH1, and the European Medicines Agency (EMA) approved inclisiran for treating high cholesterol.
|
| 2020 |
RNA interference
Inclisiran receives approval in Europe with anticipated US approval in 2021.
|
| 2020 |
RNA interference
Lumasiran receives approval in both the European Union and United States for treating primary hyperoxaluria type 1 (PH1) in pediatric and adult populations.
|
| 2020 |
Rfam
Rfam version 14.0 released, expanding coverage to include metagenomic, viral, and microRNA families.
|
| December 2020 |
RNA interference
Novartis announced positive phase III efficacy study results for inclisiran as a treatment for heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD).
|
| 2019 |
RNA interference
FDA and EMA approve givosiran for treating adults with acute hepatic porphyria (AHP).
|
| 2019 | EteRNA launched the OpenRibosome project in collaboration with the Jewett Lab at Northwestern University, focusing on enhancing the folding of modified Escherichia coli ribosomes using the iSAT cell-free ribosome construction platform. The project involves players designing 16S and 23S sequences, which are being evaluated through four feedback-based iterations to reengineer ribosomes as molecular machines capable of synthesizing unique polymers. |
| November 2019 |
RNA interference
FDA grants givosiran breakthrough therapy designation, priority review designation, and orphan drug designation for treating acute hepatic porphyria (AHP).
|
| 2018 |
RNA interference
FDA approved patisiran, the first siRNA-based drug.
|
| 2018 |
RNA interference
Patisiran becomes the first double-stranded siRNA-based medication approved, developed by Alnylam Pharmaceuticals to suppress the TTR gene responsible for hereditary ATTR amyloidosis.
|
| 2017 |
Rfam
Rfam version 13.0 released, shifting to a genome-centric resource for non-coding RNA families.
|
| 2014 |
Rfam
Rfam version 12.0 released with updates to the RNA families database.
|
| August 2012 |
Rfam
Rfam version 11.0 released, containing 2,208 RNA families, marking 10 years of RNA family documentation.
|
| 2011 |
Rfam
Rfam released with Wikipedia integration and introduced 'decimal' release versioning.
|
| 2010 |
RNA interference
First-in-human Phase I clinical trial started, using a nanoparticle delivery system to target solid tumors.
|
This contents of the box above is based on material from the Wikipedia articles EteRNA, Rfam & RNA interference, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.